iTeos Therapeutics to Present at Wedbush PacGrow Healthcare Conference 2021

Rhea-AI Summary

iTeos Therapeutics, Inc. (Nasdaq: ITOS) has announced the presentation of its CEO, Michel Detheux, at the Wedbush PacGrow Healthcare Conference on August 10, 2021, at 2:20 p.m. ET. The conference will feature a live webcast available on the company’s website, with an archived replay accessible for 30 days.

iTeos focuses on developing innovative immuno-oncology therapeutics, including two promising clinical-stage programs. Their lead candidate, EOS-448, targets anti-TIGIT mechanisms, showing preliminary clinical activity, while inupadenant aims to combat cancer immunosuppression.

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Aug. 03, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and Chief Executive Officer, will present at the upcoming Wedbush PacGrow Healthcare Conference 2021 on Tuesday, August 10, 2021 at 2:20 p.m. ET.

A live webcast of the presentation will be available on the Investors section of the company’s website at https://www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation.

About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. The Company’s innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology. The initial antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism. An open-label Phase 1 clinical trial of EOS-448 is ongoing in adult cancer patients with advanced solid tumors with preliminary data indicating preliminary clinical activity as a monotherapy and a favorable tolerability profile. The Company is also advancing inupadenant, a first insurmountable adenosine A2A receptor antagonist in clinical development tailored to overcome cancer immunosuppression. iTeos is conducting an open-label multi-arm Phase 1/2a clinical trial of inupadenant in adult cancer patients with advanced solid tumors. Preliminary results indicate encouraging single-agent activity as well as the identification of a potential predictive biomarker. iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium.

For further information, please contact:

Investor Contact:
Ryan Baker
iTeos Therapeutics, Inc.
Ryan.Baker@iteostherapeutics.com

Media Contact:
media@iteostherapeutics.com

FAQ

What is the date of iTeos Therapeutics' presentation at the Wedbush PacGrow Healthcare Conference 2021?

The presentation is scheduled for August 10, 2021, at 2:20 p.m. ET.

Where can I watch the iTeos Therapeutics presentation live?

The live webcast will be available on the Investors section of the iTeos Therapeutics website.

What are the main immuno-oncology products being developed by iTeos Therapeutics?

iTeos is developing EOS-448, an anti-TIGIT antibody, and inupadenant, an A2A receptor antagonist.

What is the status of the clinical trials for EOS-448 and inupadenant?

EOS-448 is in a Phase 1 trial showing preliminary activity, while inupadenant is in a Phase 1/2a trial with encouraging results.

How can I access the archived replay of the iTeos Therapeutics presentation?

The archived replay will be available for approximately 30 days after the presentation on the company’s website.